---
title: "Alkermes (ALKS) news: class action and merger"
url: "https://aibio.space/companies/alkermes/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "ALKS class action and merger news. Alkermes news for investors: Alkermes sells medicines for addiction, schizophrenia, bipolar disorder and narcolepsy, and…"
---

Desk view · Opinion · Updated Oct 22, 2026

## Alkermes is betting its sleep purchase and orexin drugs can outrun Vivitrol generics

Alkermes has a growing commercial base, a new CEO and a young orexin pipeline that has yet to report Phase 3 data. Generic Vivitrol in 2027 and the debt from the Avadel purchase are the main financial constraints. The next dated tests are alixorexton in idiopathic hypersomnia and the LUMRYZ filing.

Read the full desk view

aibio.space Investor Rank · Opinion

**6** /10 Neutral view

Revenue grew 27% with the Avadel deal, but generic Vivitrol from January 2027, new term debt and an orexin pipeline without phase 3 data constrain it.

- **Technology**: 1/2

- **Odds**: 1/2

- **Balance sheet**: 1/2

- **Risk**: 1/2

- **Momentum**: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. [How the rank works](https://aibio.space/disclosures/#rank).

- **Technology**: **Early but differentiated.** Orexin 2 agonists are a young drug class, and alixorexton has Phase 3 studies running alongside an approved sleep product, LUMRYZ.

- **Odds**: **Mixed.** LUMRYZ in idiopathic hypersomnia has a positive Phase 3 result, while alixorexton Phase 3 results and ADHD Phase 2 data are still to come.

- **Balance sheet**: **Adequate but leveraged.** $691.6 million in cash at June 30 against $1.525 billion of term loans borrowed for the Avadel deal.

- **Main risk**: **Generic Vivitrol.** Teva can launch a licensed generic from Jan. 15, 2027, and the product is guided to $460 million to $480 million of 2026 sales.

- **Watch next**: **Vibrance-3 topline.** Phase 2 results for alixorexton in idiopathic hypersomnia are expected toward year-end 2026.

## Top news on Alkermes

1. 2026-08-12 Debt Financing [Alkermes amends term loan credit agreement, cutting interest spreads](https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/) JPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%.
2. 2026-07-28 Legal [Alkermes sues Teva, Apotex and MSN over proposed generic Lybalvi](https://aibio.space/news/alkermes-sues-teva-apotex-msn-proposed-generic-lybalvi/) Two Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months.
3. 2026-07-28 Legal [Alkermes faces direct-purchaser antitrust class action over Vivitrol patent](https://aibio.space/news/alkermes-faces-direct-purchaser-antitrust-class-action-vivitrol-patent/) Value Drug Company sued Alkermes, Inc. and Alkermes Pharma Ireland Limited in Massachusetts in October 2025. A December 2025 motion to dismiss is the latest step the 10-Q reports.
4. 2025-10-22 Mergers [Alkermes agrees to buy Avadel for $18.50 a share plus CVR, with JPMorgan bridge loan](https://aibio.space/news/alkermes-agrees-buy-avadel-18-50-share-plus-cvr-jpmorgan-bridge-loan/) Alkermes offers $18.50 a share in cash, plus a CVR that pays only if two conditions are met by December 31, 2028. The deal is funded with cash and a JPMorgan bridge loan, and it has not closed.

## Dates

**Toward year-end 2026**
Topline results from the Phase 2 Vibrance-3 study of alixorexton in idiopathic hypersomnia [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)

**By end of 2026**
Planned sNDA filing for LUMRYZ in idiopathic hypersomnia [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-ex99_1.htm)

**Jan. 15, 2027**
Earliest date Teva is licensed to market a generic version of Vivitrol in the U.S. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/alks-ex99_1.htm)

**2027**
Phase 2 data for ALKS 7290 in adults with ADHD [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-ex99_1.htm)

**March 1, 2028**
Earliest date Alkermes may market LUMRYZ for idiopathic hypersomnia [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-ex99_1.htm)

## The money

$691.6 million in cash, cash equivalents and total investments at June 30, 2026 (up from $538.2 million at March 31). Alkermes borrowed $1.525 billion in term loans due 2031 to help fund the Avadel acquisition. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)

Total revenues of $496.0 million in Q2 2026 (Vivitrol $124.5 million, Aristada $96.7 million, Lybalvi $94.0 million, LUMRYZ $96.6 million). [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)

## Risks on the record

- Teva is licensed to launch a generic Vivitrol from Jan. 15, 2027; Alkermes ended its Amneal authorized-generic agreement in July 2026. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/alks-ex99_1.htm)
- GAAP net loss guided at $95 million to $115 million for 2026 after the Avadel acquisition. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)
- The ALKS 7290 ADHD result came from a study the company said was not powered to detect statistically significant differences. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-ex99_1.htm)

## Questions investors ask

### What is aibio.space's Investor Rank for Alkermes?

6 out of 10, our neutral view. Revenue grew 27% with the Avadel deal, but generic Vivitrol from January 2027, new term debt and an orexin pipeline without phase 3 data constrain it. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. [Source](https://aibio.space/disclosures/#rank)

### What did Alkermes report in its second-quarter 2026 results?

Revenue was $496.0 million, up from $390.7 million a year earlier, with GAAP net income of $0.5 million and adjusted EBITDA of $139.2 million. Alkermes kept its 2026 revenue guidance at $1,730 million to $1,840 million. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)

### Who is the CEO of Alkermes?

Blair Jackson became chief executive on Aug. 1, 2026. Richard Pops, the previous CEO, remains chairman of the board. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm)

### What are the results of the ALKS 7290 ADHD study?

In a Phase 1b study of 50 adults with ADHD, median AISRS scores fell 14.0 points on 20 mg and 19.0 points on 50 mg at day 14. Alkermes said the study was not powered to detect statistically significant differences, and a Phase 2 study with data in 2027 is enrolling. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-ex99_1.htm)

### When can generic Vivitrol launch?

Alkermes licensed Teva to market a generic Vivitrol in the U.S. starting Jan. 15, 2027, or earlier under customary circumstances. Alkermes ended its separate authorized-generic agreement with Amneal in July 2026. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000095017023045176/alks-ex99_1.htm)

### What is Alkermes' LUMRYZ filing plan for idiopathic hypersomnia?

After positive Phase 3 REVITALYZ results in May 2026, Alkermes plans to file an sNDA with the FDA by the end of 2026. It cannot market LUMRYZ for the condition before March 1, 2028. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-ex99_1.htm)

### What is the latest Alkermes (ALKS) stock news?

Our latest story on Alkermes, dated Aug 12, 2026: "Alkermes amends term loan credit agreement, cutting interest spreads". JPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%. [Source](https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/)

### Does Alkermes have debt, a term loan or convertible notes?

Our latest debt story, dated Aug 12, 2026: "Alkermes amends term loan credit agreement, cutting interest spreads". JPMorgan Chase Bank, N.A. is administrative agent. The amendment cuts the spread on term loan A by 0.75% and on term loan B by 0.50%. [Source](https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/)

### How much cash does Alkermes have?

From our story of Aug 12, 2026: Against $511.5 million of cash at June 30, 2026, the term loans show principal of $745,312,500.00 and $773,062,500. [Source](https://aibio.space/news/alkermes-amends-term-loan-credit-agreement-cutting-interest-spreads/)

### Is Alkermes facing a lawsuit?

Our latest legal story, dated Jul 28, 2026: "Alkermes sues Teva, Apotex and MSN over proposed generic Lybalvi". Two Alkermes subsidiaries filed Hatch-Waxman patent suits in New Jersey and Delaware against Teva Pharmaceuticals, Apotex and MSN entities. FDA approval of each generic application is stayed for up to 30 months. Claims in lawsuits are allegations until a court rules. [Source](https://aibio.space/news/alkermes-sues-teva-apotex-msn-proposed-generic-lybalvi/)

### Is Alkermes being acquired or merging?

Our latest merger story, dated Oct 22, 2025: "Alkermes agrees to buy Avadel for $18.50 a share plus CVR, with JPMorgan bridge loan". Alkermes offers $18.50 a share in cash, plus a CVR that pays only if two conditions are met by December 31, 2028. The deal is funded with cash and a JPMorgan bridge loan, and it has not closed. [Source](https://aibio.space/news/alkermes-agrees-buy-avadel-18-50-share-plus-cvr-jpmorgan-bridge-loan/)

### What is Alkermes's market cap?

We do not publish live share prices. In its annual report, Alkermes plc put the market value of shares held by non-affiliates (public float) at $4.66 billion as of Jun 30, 2025. Source

### Is Alkermes a smaller reporting company?

SEC records list Alkermes plc's filer category as: Large accelerated filer. Source

### Where is Alkermes headquartered?

SEC records list its business address as CONNAUGHT HOUSE, DUBLIN 4, Ireland, 00000. Source

### When does Alkermes's fiscal year end?

Alkermes plc's fiscal year ends on December 31, per SEC records. Source

## Legal and investor matters

Checked against Alkermes filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

The 10-Q filed 2026-07-28 states that at June 30, 2026 there were no potential material losses from claims, asserted or unasserted, or legal proceedings that the Company determined were probable of occurring. The same filing describes one putative class action, an antitrust suit by a purported direct purchaser of Vivitrol. It covers that quarterly report only. [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm)

1. 2026-08-12 Financing Alkermes cuts interest spreads on term loans A and B On August 12, 2026, Alkermes plc signed Amendment No. 1 to the credit agreement it entered on February 12, 2026 in connection with the Avadel acquisition. The amendment reduced the interest rate spread on the term loan A facility by 0.75% and on the term loan B facility by 0.50%. The filing states outstanding principal of $745,312,500 on term loan A, maturing February 12, 2031, and $773,062,500 on term loan B, maturing August 12, 2031. [Alkermes Form 8-K, 2026-08-12](https://www.sec.gov/Archives/edgar/data/1520262/000119312526345901/alks-20260812.htm)
2. 2026-07-15 Litigation Second Circuit affirms ruling for Alkermes in Acorda arbitration dispute Acorda Therapeutics asked the U.S. District Court for the Southern District of New York in January 2023 to modify an October 2022 arbitral award and add about $66.0 million in damages. The court confirmed the award in August 2023 and declined to increase it. Acorda appealed. On July 15, 2026, the U.S. Court of Appeals for the Second Circuit affirmed the decision in favor of Alkermes. U.S. Court of Appeals for the Second Circuit · Status: appealed [Alkermes Form 10-Q, 2026-07-28](https://www.sec.gov/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm)
3. 2026-02-12 Financing Alkermes completes Avadel acquisition and signs $1.525 billion in term loans Alkermes completed its acquisition of Avadel Pharmaceuticals plc on February 12, 2026, for $21.00 per share in cash plus a contingent value right. On the same day, in connection with the acquisition, it entered a credit agreement providing a senior secured term loan A of up to $750 million and a term loan B of up to $775 million, and borrowed the full $1.525 billion available. The 8-K says the commitments, together with cash on hand, were sufficient to fund the acquisition, so the company terminated its bridge loan. [Alkermes Form 8-K, 2026-02-12](https://www.sec.gov/Archives/edgar/data/1520262/000119312526047682/d43532d8k.htm)
4. 2025-11-18 Other Alkermes raises cash offer for Avadel to $21.00 per share On November 18, 2025, Alkermes and Avadel Pharmaceuticals plc amended their October 22, 2025 transaction agreement. The cash consideration rose from $18.50 to $21.00 per Avadel share, and the contingent value right of $1.50 per share was unchanged. Alkermes also amended its bridge term loan to provide up to $1,512,562,923.28 to fund the cash consideration and fees. [Alkermes Form 8-K, 2025-11-19](https://www.sec.gov/Archives/edgar/data/1520262/000119312525286909/d858713d8k.htm)
5. 2025-10-28 Regulatory Alkermes discloses subpoena and civil investigative demands In its 10-Q filed October 28, 2025, Alkermes disclosed that it had received a subpoena and civil investigative demands from U.S. state and federal governmental authorities, and that it is cooperating. The filings do not name the agencies or the subject. By the 10-Q filed July 28, 2026, the disclosure referred to a civil investigative demand from a U.S. state governmental authority. Status: pending [Alkermes Form 10-Q, 2025-10-28](https://www.sec.gov/Archives/edgar/data/1520262/000119312525252524/alks-20250930.htm)
6. 2025-10-02 Litigation Putative class action alleges Vivitrol patent was wrongly enforced On October 2, 2025, Value Drug Company filed an antitrust complaint against Alkermes, Inc. and Alkermes Pharma Ireland Limited in the U.S. District Court for the District of Massachusetts, on behalf of a putative class of direct purchasers of Vivitrol. The complaint alleges a Vivitrol patent was fraudulently obtained, improperly listed in the Orange Book and wrongfully enforced. The defendants moved to dismiss in December 2025. The company intends to defend itself. U.S. District Court for the District of Massachusetts · Status: pending [Alkermes Form 10-Q, 2025-10-28](https://www.sec.gov/Archives/edgar/data/1520262/000119312525252524/alks-20250930.htm)
7. 2025-08-15 Litigation Alkermes sues Teva, Apotex and MSN over generic Lybalvi Alkermes subsidiaries filed patent infringement suits over proposed generic Lybalvi, starting August 15, 2025 against Teva in the U.S. District Court for the District of New Jersey, then against Apotex (in New Jersey and Delaware) and MSN Laboratories. The suits followed paragraph IV certification notices on the generic applications. Alkermes says filing each suit triggered a stay of FDA approval of up to 30 months. A further Apotex suit was filed in New Jersey on June 18, 2026 and consolidated with the earlier one on July 23, 2026. U.S. District Court for the District of New Jersey · Status: pending [Alkermes Form 10-Q, 2025-10-28](https://www.sec.gov/Archives/edgar/data/1520262/000119312525252524/alks-20250930.htm)

## Pipeline

| Program | Indication | Stage |
|---|---|---|
| Alixorexton (orexin 2 agonist) | Narcolepsy type 1 and type 2 | Phase 3 (Brilliance studies); Breakthrough Therapy designation for NT1 [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526270280/alks-ex99_1.htm) |
| Alixorexton | Idiopathic hypersomnia | Phase 2 (Vibrance-3); topline expected toward year-end 2026; FDA orphan designation [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm) |
| LUMRYZ (sodium oxybate, extended-release) | Idiopathic hypersomnia | Phase 3 REVITALYZ met primary endpoint; sNDA planned by end of 2026 [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-ex99_1.htm) |
| ALKS 7290 (orexin 2 agonist) | Adult ADHD | Phase 2 enrolling (about 312 participants); data expected 2027 [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-ex99_1.htm) |
| Valiloxybate | Oxybate candidate (from Avadel) | Phase 1 [Source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526047682/d43532dex991.htm) |

Opinion · Devil's advocate

## Fact-check-o-meter

Some gaps

Alkermes' two new data releases lead with positive framing and state the design limits in the body text

Alkermes' financial figures match its 10-Q, and both new clinical releases state their design limits in the body text. The gaps are in headlines and framing: a 10-patient placebo group is called proof-of-concept, and a two-week withdrawal test is described as improvement over placebo. The 10-Q also discloses an antitrust class action the earnings release does not mention.

1. Science · weight medium ADHD "proof-of-concept" rests on 50 patients and no powered comparison **The company said:** "Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)" [source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-ex99_1.htm) **The record says:** The same release says 50 adults were randomized 4:1, with 10 on placebo, for 14 days, and that "The study was not designed or powered to detect statistically significant differences between treatment groups." The reported AISRS and CGI-S figures are median reductions from baseline in the 20 mg and 50 mg groups. The release gives no placebo-group figures. ClinicalTrials.gov lists the planned phase 2 (NCT07755410) as randomized and double-blind, about 312 participants, with a primary outcome of change in AISRS total score at week 4. [source](https://clinicaltrials.gov/study/NCT07755410) **Our view:** Change from baseline in a small, short study with no reported placebo comparison cannot separate drug effect from placebo response, which is large in ADHD. The release is open about the limit, but the headline and the "first" claim go further than the data. The phase 2 is the real test.
2. Science · weight medium IH win measures worsening after withdrawal, after open-label dosing **The company said:** "LUMRYZ Met All Primary and Key Secondary Endpoints Demonstrating Statistically Significant and Clinically Meaningful Improvements Compared to Placebo in Excessive Daytime Sleepiness and Patient-Reported Disease Severity" [source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-ex99_1.htm) **The record says:** The release describes a randomized withdrawal design: "All study participants received LUMRYZ during an open-label dose titration period" and 104 participants were then randomized, with endpoints measured "to assess the worsening of symptoms for those participants on placebo as compared to those that remained on LUMRYZ." The double-blind period lasted 2 weeks. ClinicalTrials.gov lists the primary outcome as change in total ESS score over a "2 week period". [source](https://clinicaltrials.gov/study/NCT06525077) **Our view:** The result shows that stopping the drug makes patients worse within two weeks, which is a valid way to support approval. It is not the same as showing improvement versus placebo from a treatment-naive start, and it tells investors little about longer-term benefit or about how large the effect is beyond the open-label run-in. Alkermes also may not market for IH before March 1, 2028, per the release.
3. Press release vs filing · weight low "Strong financial foundation" and new acquisition debt **The company said:** "With a talented team, a strong financial foundation and exciting opportunities ahead in sleep medicine and across our neuroscience portfolio, I am honored to step into the CEO role" [source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm) **The record says:** The 10-Q says that on Feb. 12, 2026, for the Avadel acquisition, "we borrowed the full $1.525 billion available to us" under term loans. The release's balance sheet shows long-term debt of 1,476,611 (thousands) with none at Dec. 31, 2025, and a six-month GAAP net loss of $(66.0) million against second-quarter GAAP net income of $0.5 million. [source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm) **Our view:** The numbers are all in the release, and adjusted EBITDA of $139.2 million is a fair operating gauge. But the release's headline pairs it with GAAP net income of $0.5 million, and the loan balance and the six-month GAAP loss show the cost of the deal.
4. Legal and disclosure record · weight medium Antitrust class action and a state investigation disclosed **The record says:** Note 18 of the 10-Q describes an October 2025 complaint by Value Drug Company in the U.S. District Court for the District of Massachusetts, on behalf of a putative class of direct VIVITROL purchasers, which asserts antitrust claims alleging that the Company's U.S. Patent No. 7,919,499 related to VIVITROL was improperly obtained, improperly listed in the Orange Book and wrongfully enforced, delaying generic entry. Alkermes "intends to vigorously defend itself" and moved to dismiss in December 2025. The filing also says "The Company has received a civil investigative demand from a U.S. state governmental authority. The Company is cooperating with the investigation." It lists LYBALVI patent suits against Teva, Apotex and MSN in New Jersey and Delaware. The 10-Q discloses no securities litigation. [source](https://www.sec.gov/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm) **Our view:** These are allegations by a private plaintiff, not findings, and the filing says no probable material loss is determined. They concern Vivitrol, which had $124.5 million of the quarter's $496.0 million in revenue, and the earnings release does not mention them.

Documents we compared

- [Alkermes Q2 2026 results press release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-ex99_1.htm) 2026-07-28
- [Alkermes REVITALYZ phase 3 topline release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526218150/alks-ex99_1.htm) 2026-05-12
- [Alkermes ALKS 7290 phase 1b ADHD release (8-K Ex. 99.1)](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-ex99_1.htm) 2026-09-21
- [Alkermes Form 10-Q for quarter ended June 30, 2026](https://www.sec.gov/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm) 2026-07-28
- [ClinicalTrials.gov NCT07755410 (ALKS 7290 phase 2 ADHD)](https://clinicaltrials.gov/study/NCT07755410) 2026-10-07
- [ClinicalTrials.gov NCT06525077 (LUMRYZ idiopathic hypersomnia)](https://clinicaltrials.gov/study/NCT06525077) 2026-10-23

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our [right of reply](https://aibio.space/reputation/#reply).

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:ALKS on TradingView](https://www.tradingview.com/symbols/NASDAQ-ALKS/).

## SEC filings and registration

- **SEC name**: Alkermes plc.

- **CIK**: 1520262

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: ALKS (Nasdaq)

- **Fiscal year ends**: December 31

- **Filer category**: Large accelerated filer

- **Business address**: CONNAUGHT HOUSE, DUBLIN 4, Ireland, 00000

- **Phone**: 00-353-1-772-8000

- **Shares outstanding**: 167,763,272 as of 2026-07-23 (10-Q filed 2026-07-28)

- **Former names**: ANTLER SCIENCE TWO PLC; Antler Science Two Ltd

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526396065/alks-20260921.htm) filed 2026-09-21
- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526392527/alks-20260914.htm) filed 2026-09-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526345901/alks-20260812.htm) filed 2026-08-12
- [10-Q](https://www.sec.gov/Archives/edgar/data/1520262/000119312526319022/alks-20260630.htm) filed 2026-07-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526318844/alks-20260728.htm) filed 2026-07-28
- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526298004/alks-20260706.htm) filed 2026-07-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526270280/alks-20260615.htm) filed 2026-06-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1520262/000119312526232584/alks-20260520.htm) filed 2026-05-20

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001520262), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/alkermes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Alkermes (ALKS) news: class action and merger", 2026-10-31, https://aibio.space/companies/alkermes/